nach oben

Journal of Thrombosis and Thrombolysis

Erschienen in:

01.05.2009

Adherence to guidelines for the management of excessive warfarin anticoagulation

verfasst von: Emily B. Devine, Alan W. Hopefl, Ann K. Wittkowsky

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Objectives The American College of Chest Physicians (ACCP) provides guidelines for the management of excessive anticoagulation in patients receiving warfarin. This multi-site prospective cohort study evaluated patient-level practice patterns and adherence to ACCP guidelines. Methods Patients presenting with an INR ≥ 4.5 between January 3 and April 29, 2005 were observed and therapeutic management documented. Adherence was assessed retrospectively. Results Four hundred and seventeen patients from 22 centers were observed. The mean, initial INR was 7.7. At enrollment, 85% of the patients had an INR < 9 or were not bleeding; 15% were seriously bleeding. Treatment for 170 patients (41%) did not adhere to guidelines. Among those, 15% were undertreated, 48% overtreated. Lack of adherence was attributed primarily to excessive doses (mean initial dose = 6.9 mg) and inappropriate routes of administration (subcutaneous or intramuscular) of vitamin K1. Conclusion Adherence to the ACCP guidelines is low. Inappropriate use of vitamin K1 is the primary reason.

Ansell J, Hirsh J, Poller L et al (2004) The pharmacology and management of the vitamin K antagonists. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:204S–233SPubMedCrossRef

Geerts WH, Pineo GF, Heit JA et al (2004) Prevention of venous thromboembolism. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:338s–400sPubMedCrossRef

Buller HR, Agnelli G, Hull RD et al (2004) Antithrombotic therapy for venous thromboembolic disease. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:401s–428sPubMedCrossRef

Salem DN, Stein PD, AlAhmed A et al (2004) Antithrombotic therapy for valvular heart disease–native and prosthetic. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:457s–482sPubMedCrossRef

Singer DE, Albers GW, Dalen JE et al (2004) Antithrombotic therapy for atrial fibrillation. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:429s–456sPubMedCrossRef

Harrington RA, Becker RC, Ezekowitz M et al (2004) Antithrombotic therapy for coronary artery disease. The seventh ACCP conference on antithrombotic and thrombolytic Therapy. Chest 126:513s–548sPubMedCrossRef

Hanslik T, Prinseau J (2004) The use of vitamin K in patients on anticoagulant therapy: a practical guide. Am J Cardiovasc Drugs 4(1):43–55PubMedCrossRef

Whitling AM, Bussey HI, Lyons RM (1998) Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch Intern Med 158:2136–2140PubMedCrossRef

Raj G, Kumar R, McKinney P (1999) Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med 159:2721–2724PubMedCrossRef

10.

Crowther MA, Douketis JD, Schnurr T et al (2002) Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. Ann Intern Med 137:251–254PubMed

11.

DeZee KJ, Shimeall WT, Douglas KM et al (2006) Treatment of excessive anticoagulation with phytonadione (vitamin K). Arch Intern Med 166:391–397PubMedCrossRef

12.

AHFS Formulary Service (2007) American Society of Health-System Pharmacists. Bethesda, MD

13.

Pengo V, Banzato A, Garelli E et al (1993) Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. Blood Coagul Fibrinolysis 4:739–741PubMedCrossRef

14.

Weibert RE, Le DT, Kayser SR et al (1997) Correction of excessive anticoagulation with low dose oral vitamin K1. Ann Intern Med 125:959–962

15.

Watson HG, Baglin T, Laidlaw SL et al (2001) A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 115:145–149PubMedCrossRef

16.

Lubetsky A, Yonath H, Olchovsky D et al (2003) Comparison of oral vs. intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation. Arch Intern Med 163:2469–2473PubMedCrossRef

17.

Libby EN, Garcia DA (2002) A survey of oral vitamin K use by anticoagulation clinics. Arch Intern Med 162:1893–1896PubMedCrossRef

18.

Wilson SE, Douketis JD, Crowther MA (2001) Treatment of warfarin-associated coagulopathy. Chest 120:1972–1976PubMedCrossRef

19.

Fan J, Armitstead JA, Adams AG et al (2003) A retrospective evaluation of vitamin K₁therapy to reverse the anticoagulant effect of warfarin. Pharmacotherapy 23(10):1245–1250PubMedCrossRef

20.

Atreja A, El-Sameed YA, Jneid H et al (2005) Elevated international normalized ratio in the ED: clinical course and physician adherence to the published recommendations. Am J Emerg Med 23:40–44PubMedCrossRef

21.

Lousberg TR, Witt DM, Beall DG et al (1998) Evaluation of excessive anticoagulation in a group model health maintenance organization. Arch Intern Med 158:528–534PubMedCrossRef

22.

Witt DM, Humphries TL (2003) A retrospective evaluation of the management of excessive anticoagulation in an established clinical pharmacy anticoagulation service compared to traditional care. J Thromb Thrombol 15(2):113–118CrossRef

23.

Amerinet, Inc. Available from URL: http://www.amerinet-gpo1.com/. Cited: December 11, 2007

24.

Palareti G, Leali N, Coccheri S et al (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy. Lancet 348:423–428PubMedCrossRef

25.

Crowther MA, Julian J, McCarty D et al (2000) Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomized controlled trial. Lancet 356:1551–1553PubMedCrossRef

26.

Crowther MA, Ageno W, Garcia D et al (2007) Effectiveness of low dose oral vitamin K for patients with elevated INR values: results of a randomized trial examining clinical outcomes (P-S-219). XXIst congress of the international society on thrombosis and haemostasis, Geneva, July 6–12. Available from URL: http://itinerary.abstractsondemand.com/isth2007/. Cited: December 11, 2007

27.

Patel RJ, Witt DM, Saseen JJ, Tillman DJ, Wilkinson DS (2000) Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy 20(10):1159–1166PubMedCrossRef

28.

Crowther MA, Garcia D, Ageno W et al (2007) Effectiveness of low dose oral vitamin K for patients with INR values of more than 10.0; results of a prospective cohort study (O-T-022). XXIst congress of the international society on thrombosis and haemostasis, Geneva, July 6–12. Available from URL: http://itinerary.abstractsondemand.com/isth2007/. Cited: December 11, 2007

Titel: Adherence to guidelines for the management of excessive warfarin anticoagulation
verfasst von: Emily B. Devine
Alan W. Hopefl
Ann K. Wittkowsky
Publikationsdatum: 01.05.2009
Verlag: Springer US
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 4/2009
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-008-0232-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

Multilayer compression bandaging in the acute phase of deep-vein thrombosis has no effect on the development of the post-thrombotic syndrome

Warfarin in vulnerable older adults with atrial fibrillation

Romiplostim: an alternative treatment option besides rituximab for the management of steroid refractory idiopathic thrombocytopenic purpura

Impact of duration of clopidogrel prescription on outcome of DES as compared to BMS in primary angioplasty: a meta-regression analysis of randomized trials

Ischemic neuropathy and rhabdomyolysis as presenting symptoms of postpartum cardiomyopathy

Abciximab and left ventricular thrombus formation in early period of acute myocardial infarction treated with successful primary stenting